Peter S. Conti awarded 2020 Benedict Cassen Prize for pioneering work in cancer imaging

Peter S. Conti, MD, PhD, known for his pioneering work in the diagnosis and management of cancer, was awarded the Benedict Cassen Prize during the 2020 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The honor is awarded every two years by the Education and Research Foundation (ERF) for Nuclear Medicine and Molecular Imaging in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science.

The Cassen Prize Committee selected Peter Conti as the 2020 recipient in recognition of his pioneering work in the development of novel radiopharmaceuticals and clinical PET applications for cancer imaging, as well as his volunteerism and service to the molecular imaging community," said

Frances K. Keech, DHSc, RT(N), FSNMMI-TS., ERF President

During a special plenary session at SNMMI's Annual Meeting, Conti presented the Cassen Lectureship on "Molecular Imaging in 2020 and Beyond: Expect the Unexpected." He discussed insights into the potential role of molecular imaging of viral infection, relevant to the current COVID-19 crisis, along with an overview spanning his 40-plus years of work in the cancer imaging field, from the early development of radiolabeled analogs of nucleosides and amino acids to more recent work using bifunctional chelation technologies, drug conjugates and companion diagnostics, as well as multimodality imaging agents.

Conti commented, "It is an honor to be recognized by the Cassen Committee of the Education and Research Foundation and the Society of Nuclear Medicine and Molecular Imaging. It is a privilege to be considered a member of this elite group of scientists who have contributed so much to the field. I want to thank all my U.S. and international collaborators, colleagues, mentors, students, friends and family whose support and inspiration made this possible."

Conti is a tenured professor at the University of Southern California (USC) in Los Angeles, with academic appointments in the departments of radiology, biomedical engineering, and pharmaceutical sciences, and has been the director of the USC PET Imaging Science Center since its inception in 1991. He received his undergraduate degree from Johns Hopkins University in Baltimore, Maryland, and his medical degree from Cornell University Medical College in New York, NY. His doctorate in biophysics was completed at Memorial Sloan-Kettering Cancer Center. He is board certified in both nuclear medicine (ABNM) and diagnostic radiology (ABR) and is a Fellow of both the American College of Radiology and the American College of Nuclear Medicine.

Conti has published more than 300 peer-reviewed papers in the field of molecular imaging, many of which focused on the development of novel PET and hybrid imaging agents for diagnostic and theranostic applications in cancer and other diseases. He is the 2016 recipient of the SNMMI Paul C. Aebersold Award for his achievements in the basic science of nuclear medicine, and he received the SNMMI 2018 Peter Valk Award for his pioneering work in clinical PET.

The Cassen Prize honors Benedict Cassen, whose invention of the rectilinear radioisotope scanner--the first instrument capable of making an image of radiotracer distribution in body organs of living patients--was seminal to the development of clinical nuclear medicine. Conti is the 15th individual since 1994 to receive the prestigious $25,000 award from the Education and Research Foundation for Nuclear Medicine and Molecular Imaging.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MicroQuin's Space Research Paves Way for Potential Cancer Treatment